Table 1

Trial eligibility according to PICO

PopulationAdult hospitalised patients with laboratory confirmed (PCR) COVID-19 infection and ARDS according to the Berlin criteriaChildren, ARDS caused by non-SARS-COV-2 infection
InterventionFibrinolytic therapy (eg, alteplase, tenecteplase) on top of standard of careFibrinolytic therapy with other indication (eg, stroke)
ComparatorStandard of care alone
Primary outcomesChange in PaO2/FiO2 ratio (Horrowitz index) pre-to-post intervention, ventilation-free days; time to ventilator-free state, successful extubation and mortality
Safety outcomesBleeding event rate (major bleeding, clinically relevant non-major bleeding and minor bleeding as per ISTH); requirement for transfusion (packed red blood cell, platelet, fresh frozen plasma, cryoprecipitate, prothrombin complex concentrate)
Study designRandomised clinical trials, prospective observational trialsRetrospective trials, case series, case reports, animal studies, conference abstracts
  • ARDS, acute respiratory distress syndrome; ISTH, International Society on Thrombosis and Haemostasis; PaO2/FiO2 ratio, ratio of arterial oxygen partial pressure to fractional inspired oxygen.